Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
A meta-analysis including EMPA-REG OUTCOME (empagliflozin), CANVAS Program (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), CREDENCE (canagliflozin) and VERTIS CV (ertugliflozin) demonstrated that SGLT2 inhibitors reduced MACE by 10% (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.850.95) and hospitalization for heart failure by 32% (HR 0.68, 95% CI 0.610.76) compared to placebo [6]
But most patients discontinue treatment 11 out of 12 stop taking GLP-1s within three years and for many, the weight returns within 18 months. Phase 2 marks a shift
Vogel J, Cinatl J, Dauletbaev N, et al
GLP1-RAs effects on WL are well-established in the general population and in patients with diabetes [49,50,51,52,53]
US$ 28.77
US$ 21.90
US$ 26.34
US$ 28.47
US$ 21.58
US$ 28.46
US$ 21.82
US$ 29.87
